Osimertinib vs Rituximab
Osimertinib vs Rituximab: Overview
This comparison examines the pharmacological differences between Osimertinib and Rituximab.
Mechanism of Action
Osimertinib: Third-generation irreversible EGFR TKI targeting T790M resistance mutation and activating mutations.
Rituximab: Chimeric anti-CD20 IgG1 monoclonal antibody inducing B-cell depletion via CDC, ADCC, and apoptosis.
Pharmacokinetics
Half-life: Osimertinib — 48 hours; Rituximab — 22 days.
Chemical Properties
Molecular Formula: Osimertinib — C28H33N7O2.
Molecular Weight: Osimertinib — 499.6050 g/mol.
Type: Osimertinib — Small molecule; Rituximab — Antibody.